Login to Your Account



More Investment, Less Return?

Planned R&D Hike Gives Gilead Investors Pause

By Jennifer Boggs


Monday, August 4, 2008
With Gilead Sciences Inc. posting strong, even "record" sales of its HIV drug franchise for the second quarter, and launching the first of two Phase III studies of promising once-daily, HIV integrase inhibitor elvitegravir, the Foster City, Calif.-based firm's quarterly progress should have sounded like music to investors' ears. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription